Archive · 6 Aug 2026
Navin Fluorine rises 8% as brokerages issue split targets
A company called Navin Fluorine makes special chemicals that other companies use.
It recently told investors that it did better in the first three months of the year than everyone expected.
Because of that good news, its shares went up by 8% in one day.
A share is a little piece of the company that people can buy and sell.
Smart money experts called analysts study the company and guess what its shares will be worth later.
Some analysts are very excited and think the shares will be worth much more, maybe as much as Rs 9,600.
Other analysts think the shares are already too expensive and say they might be worth only Rs 4,700.
The company is also making its factory in Dahej bigger, which could earn it a lot of extra money.
One project with a partner called Chemours is taking a little longer than planned.
When experts disagree like this, it means nobody knows for sure what will happen next.
Navin Fluorine shares rose 8% after the company reported an operational beat in Q1FY27 with improved growth visibility.
Ambit retained 'BUY' with a target of Rs 9,071 and raised FY27/FY28E EPS estimates by 16.8%/9.7%, though the article headline cites Ambit as most bullish at Rs 9,600.
UBS and Jefferies suggested 'Buy' with targets of Rs 9,045 and Rs 9,000, while Citi has 'Sell' at Rs 7,200 and Morgan Stanley is 'Underweight' at Rs 5,720.
Equirus is the most bearish broker with a target of Rs 4,700, while JM Financial maintained 'BUY' and raised its target by 10% to Rs 9,000.
Elara Securities said Dahej MPP debottlenecking is on track for Q3FY27 with peak revenue potential of Rs 140-160 crore, while the Chemours liquid-cooling project slipped to end-Q2FY27.
- Who
- Navin Fluorine and analysts at Ambit, Equirus, UBS, Jefferies, Citi, Morgan Stanley, Elara Securities, JM Financial and Motilal Oswal Financial Services.
- What
- Navin Fluorine shares rose 8% after a Q1FY27 operational beat, and brokerages issued mixed ratings with target prices ranging from Rs 4,700 to Rs 9,600.
- When
- Following the company's Q1FY27 results; the article does not specify a calendar date.
- Where
- Dahej, the site of Navin Fluorine's MPP plant mentioned in the article.
- Why
- Improved growth visibility, robust FY27 order visibility for agrochem molecules and the Q1FY27 operational beat led most brokerages to raise estimates and targets.
Bullish Analysts
Bearish Analysts
Valuation and target price
Bullish Analysts
Ambit (Rs 9,600 per headline), Elara Securities (Rs 9,185), UBS (Rs 9,045), Jefferies (Rs 9,000) and JM Financial (Rs 9,000) see significant upside in the stock.
Bearish Analysts
Equirus (Rs 4,700), Morgan Stanley (Rs 5,720) and Citi (Rs 7,200) see the stock as overvalued or expect it to fall.
Growth outlook
Bullish Analysts
A Q1FY27 operational beat, constructive pricing, FY27 order visibility for 4-5 agrochem molecules and capacity ramp-up support sustainable growth momentum.
Bearish Analysts
Citi has a 'Sell' rating, Morgan Stanley is 'Underweight', and MOFSL's target of Rs 8,300 implies only limited downside from current levels.
- Stock movement
- +8% around the time of the Q1FY27 review
- Most bullish target
- Rs 9,600 (Ambit, per article headline; Ambit's own note states Rs 9,071)
- Most bearish target
- Rs 4,700 (Equirus)
- Elara Securities
- 'Buy', target Rs 9,185
- UBS / Jefferies
- 'Buy' with targets of Rs 9,045 / Rs 9,000
- Citi / Morgan Stanley
- 'Sell' at Rs 7,200 / 'Underweight' at Rs 5,720
- JM Financial
- 'BUY', target raised 10% to Rs 9,000; FY27/FY28E EPS raised 13%/5%
- Dahej MPP project
- Debottlenecking on track for Q3FY27, peak revenue potential Rs 140-160 crore